Law360 recognized the firm’s successful argument before the Seventh Circuit on behalf of Pfizer. Williams & Connolly served as lead appellate counsel for Pfizer in this dispute involving the company’s drug, Depo-Testosterone (“Depo-T”). In the multidistrict litigation, plaintiffs alleged that Pfizer was liable in failing to properly warn patients using Depo-T that they could suffer a heart attack or other cardiovascular injury. The question presented in this case was whether the plaintiffs’ failure-to-warn claims are pre-empted by federal law because the Food, Drug and Cosmetic Act, and regulations promulgated thereunder, precluded Pfizer from unilaterally changing the label on Depo-T. The case was argued in the Seventh Circuit on October 23, 2017.
On January 19, 2018, the court declined to revive claims in connection with the company’s drug, Depo-T, finding the suits’ state law claims were preempted by federal drug regulations.
Kannon Shanmugam, Allison Rushing, and Eden Schiffmann represent Pfizer.
Click here to view the article.